Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)

v3.25.1
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - GBP (£)
Dec. 31, 2024
Dec. 31, 2023
Prepaid Expenses And Other Current Assets    
Other receivables £ 7,837 £ 51,584
VAT owed to the Company 80,411 135,642
Prepaid clinical trial costs 307,519 307,519
Deferred clinical trial testing costs 1,177,500 1,177,500
Deferred investor relations activity costs 1,523,206
Deferred collaboration agreement costs 331,283
Other prepayments 479,284 522,480
Total prepaid expenses and other current assets £ 3,907,040 £ 2,194,725